Valeritas Holdings, Inc. (VLRX) Receives Consensus Recommendation of “Strong Buy” from Analysts

Valeritas Holdings, Inc. (NASDAQ:VLRX) has earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 1-year consensus price objective of $13.50 for the company and are expecting that the company will post ($1.69) EPS for the current quarter, according to Zacks. Zacks has also assigned Valeritas an industry rank of 165 out of 265 based on the ratings given to its competitors.

Separately, ValuEngine raised Valeritas from a “strong sell” rating to a “sell” rating in a research note on Friday.

Valeritas (VLRX) opened at $4.64 on Friday. Valeritas has a one year low of $2.00 and a one year high of $40.96. The company has a debt-to-equity ratio of 3.54, a current ratio of 3.88 and a quick ratio of 3.20.

A hedge fund recently bought a new stake in Valeritas stock. C WorldWide Group Holding A S purchased a new position in shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 233,952 shares of the company’s stock, valued at approximately $1,603,000. C WorldWide Group Holding A S owned 3.42% of Valeritas at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.74% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at

About Valeritas

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas (VLRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with's FREE daily email newsletter.

Leave a Reply